Eph inhibitor 1是一种有效的 Eph 受体抑制剂，具有研究神经系统疾病的潜力。

Urolithin D 是一种EphA受体竞争性可逆拮抗剂，对 EphA 受体具有亚型选择性。

123C4 是一种有效的、选择性和竞争性的受体酪氨酸激酶 EPHA4 激动剂，其 Ki 值为 0.65 μM。

ALW-II-41-27是一种Eph家族酪氨酸激酶抑制剂，对Eph2的IC50为11 nM。

NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition and also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.

KYL is a selective EphA4 receptor tyrosine kinase antagonist that inhibits EphA4-EphrinA5 interactions. KYL binds to the ephrin-binding domain of EphA4.

ML 786 2HCl is a potent Raf kinase inhibitor with IC50s of 2.1, 2.5 and 4.2 nM for B-RafV600E, C-Raf and wild-type B-Raf, respectively.

JI-101 is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR-β), and ephrin type-B receptor 4 (EphB4).

XL647 or tesevatinib inhibits EGFR, HER2, VEGFR and EphB4 with potential antineoplastic activity.